Niri Tetsuro, Inoue Shin-Ichi, Akazawa Satoru, Nishikido Shinpei, Miwa Masaki, Kobayashi Masakazu, Yui Katsuyuki, Okita Minoru, Kawakami Atsushi, Abiru Norio
Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Division of Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxae093.
Haploinsufficiency of the transcription factor interferon-regulatory factor 4 (IRF4) prevents the onset of spontaneous diabetes in NOD mice. However, the immunological mechanisms of the IRF4-mediated disease regulation remain unclear. This study aims to investigate the role of IRF4 in the pathogenesis of autoimmune diabetes by conducting adoptive transfer experiments using donor IRF4 gene-deficient CD4+ T cells from BDC2.5-transgenic (Tg) NOD mice and recipient Rag1-knockout NOD mice, respectively. Through this approach, we analyzed both clinical and immunological phenotypes of the recipient mice. Additionally, IRF4-deficient BDC2.5 CD4+ T cells were stimulated to assess their immunological and metabolic phenotypes in vitro. The findings revealed that diabetes was completely prevented in the recipients with Irf4-/- T cells and was approximately 50% lower in those with Irf4+/- T cells than in wild type (WT) controls, whereas Irf4-/- recipients with WT T cells only showed a delayed onset of diabetes. Islet-infiltrating T cells isolated from recipients with Irf4+/- T cells exhibited significantly lower proliferation and IFN-γ/IL-17 double-positive cell fraction rates compared with those in WT controls. Irf4-/- BDC2.5 CD4+ T cells stimulated in vitro showed a reduced number of cell divisions, decreased antigen-specific T-cell markers, and impairment of glycolytic capacity compared with those observed in WT controls. We concluded that IRF4 predominantly regulates the diabetogenic potential in a dose-dependent manner by mediating the proliferation and differentiation of islet-infiltrating T cells while playing an adjunctive role in the innate immune responses toward diabetes progression in NOD mice.
转录因子干扰素调节因子4(IRF4)的单倍剂量不足可预防非肥胖糖尿病(NOD)小鼠自发性糖尿病的发生。然而,IRF4介导的疾病调节的免疫机制仍不清楚。本研究旨在通过分别使用来自BDC2.5转基因(Tg)NOD小鼠的供体IRF4基因缺陷型CD4 + T细胞和受体Rag1基因敲除型NOD小鼠进行过继转移实验,来研究IRF4在自身免疫性糖尿病发病机制中的作用。通过这种方法,我们分析了受体小鼠的临床和免疫表型。此外,对IRF4缺陷型BDC2.5 CD4 + T细胞进行刺激,以在体外评估其免疫和代谢表型。研究结果显示,接受Irf4 - / - T细胞的受体小鼠完全预防了糖尿病,接受Irf4 + / - T细胞的受体小鼠的糖尿病发生率比野生型(WT)对照低约50%,而接受WT T细胞的Irf4 - / - 受体小鼠仅表现出糖尿病发病延迟。与WT对照相比,从接受Irf4 + / - T细胞的受体小鼠中分离出的胰岛浸润性T细胞表现出明显较低的增殖率和IFN-γ/IL-17双阳性细胞分数率。与WT对照相比,体外刺激的Irf4 - / - BDC2.5 CD4 + T细胞显示细胞分裂数量减少、抗原特异性T细胞标志物减少以及糖酵解能力受损。我们得出结论,IRF4主要通过介导胰岛浸润性T细胞的增殖和分化以剂量依赖性方式调节致糖尿病潜能,同时在NOD小鼠糖尿病进展的固有免疫反应中起辅助作用。